Tempus AI climbs on $1.1 billion contract value

Shares of genetics-testing firm Tempus AI TEM.O up 10.4% at $73.19 premarket

Reports record total contract value of over $1.1 bln and net revenue retention of ~126%

Says it signed data agreements with more than 70 customers in 2025, including AstraZeneca AZN.L, Pfizer PFE.N, Merck MRK.N and other major drugmakers

Co says engagement with life sciences firms at "record levels," giving visibility to continued growth in 2026 and beyond

Preliminary 2025 data & applications revenue estimated at $316 mln, up ~31% YoY

Says FY prelim 2025 revenue about $1.27 billion, up roughly 83%

TEM stock gained ~76% over the past year